We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Microscan Demonstrates Advanced Technology at Scientific Meeting

By LabMedica International staff writers
Posted on 01 Aug 2017
Microscan Systems, Inc. More...
(Renton, WA, USA), a provider of embedded clinical barcode readers and machine vision solutions for life sciences, demonstrated advancements of its MicroHAWK platform for barcode reading and machine vision, LVS label verification, and print quality inspection systems at the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services.

Microscan’s barcode reading, machine vision, and verification technology serves a wide range of automation and OEM applications and the company’s solutions range from barcode reading, tracking, and traceability to complex machine vision measurement, guidance, barcode verification, and print quality grading. The company was among over 750 exhibitors who displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation at the 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from August 1-3.

Microscan’s MicroHAWK platform provides users a single hardware solution with options to meet any barcode decoding or inspection task, in any integration space, and with scalability to meet unique current and future requirements. The hardware has been designed with life science and OEM applications in mind, focused on specific feature customizations in enclosed devices that can be manufactured and supported by Microscan on a long-term basis to accommodate instrument lifecycles.

The company’s miniaturization technology allows medical device manufacturers, laboratories, and OEMs to use MicroHAWK devices in the most space-constrained installations. For instance, the extremely small size of MicroHAWK smart cameras enables them to be easily embedded for automating processes such as specimen and reagent identification, tracking labware presence and absence, cap type and color identification, dimensional measurements such as tube height and diameter, automated alignment and robotic guidance within turnkey medical devices and instruments.

MicroHAWK barcode readers, which were on display at the event, are equipped with Autofocus technology, enabling flexible positioning in medical equipment and other integration environments. MicroHAWK with Autofocus can read symbols at any distance, while fixed-focus models are factory-configured to decode at set focal distances. Autofocus models offer both an automatic autofocus for continuous symbol location and decoding, as well as software-programmable focus - which allows users the option to set fixed focal distances for Autofocus units from Microscan’s Weblink software user interface. Through direct integration of the Autofocus lens technology into MicroHAWK, Microscan eliminates additional cost to the user, minimizes device size, avoids integration complexity and removes the need for additional optical accessories.

Also on display was Microscan’s LVS-9580 Handheld Barcode Verifier - a high-performance handheld solution for off-line barcode verification to ISO/IEC and GS-1 standards. The LVS-9580 reads and analyzes multiple types of linear (1D) and two-dimensional (2D) barcodes up to 3.0 inches (76.19 mm) wide and up to 2.25 inches (57.15 mm) tall, located on a wide range of surfaces. It enables users to test newly designed labels for quality and compliance issues before printing.

Microscan also ran live demonstrations of its LVS-7510 Print Quality Inspection System, configurable into manufacturing lines and printers to check label accuracy on the fly during label printing. It is used for 100% label inspection including 1D/2D barcode verification, OCR, serialization and blemish detection in medical device manufacturing, packaging and other industries. The LVS-7510 identifies errors in code readability and compliance as codes are printed, allowing manufacturers to address printing or formatting issues before incurring fines and scrapped product down the supply chain. Both in-line and off-line verification solutions address the growing need for compliance to the FDA’s Unique Device Identification (UDI) initiative, GS1 and HIBCC data structure, as well as other regulated barcoding and product serialization standards.

Related Links:
Microscan Systems


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Urine Analyzer
respons® UDS100
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.